Study of clazakizumab for people at high heart risk
Part of Heart & circulation, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests an investigational drug called clazakizumab to see if it can reduce the risk of heart attacks, strokes, or cardiovascular death in people with high inflammation and certain chronic conditions like heart disease, diabetes, or kidney disease. Participation may help researchers learn if this treatment is safe and effective for this population.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a blood test result showing high-sensitivity C-reactive protein (hsCRP) between 2 and 15 mg/L.
- You must have at least one of these conditions: atherosclerosis, obesity (BMI ≥30), type 2 diabetes, high blood pressure, or chronic kidney disease stages 3 or 4.
- You must not have had a recent heart attack, stroke, or heart failure hospitalization within the last 60 days.
- Your blood pressure must be well-controlled (below 160/100 mmHg).
- You must not have active infections (including tuberculosis, hepatitis B or C), autoimmune diseases, or a weakened immune system.
- You must not have a history of gastrointestinal ulcers, diverticulitis, or major gastrointestinal surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication, AZD0780, to see if it helps prevent major cardiovascular events like heart attacks or strokes in people who already have heart or blood vessel disease, or are at high risk for a first event. It might be a good fit if your cholesterol isn't well-controlled despite current treatments.
This trial tests if secukinumab, a medicine for inflammation, can improve heart and kidney outcomes in people with cardiorenal metabolic syndrome and atherosclerotic cardiovascular disease. It may help if you have conditions like obesity, diabetes, high blood pressure, kidney issues, and hardened arteries.
This trial looks at how treating or managing conditions like diabetes, prediabetes, obesity, kidney disease, or high cholesterol affects artery plaque over time. It may help researchers find ways to slow plaque buildup and related heart risks.
This study tests an experimental drug called clazakizumab (CSL300) to see if it can reduce inflammation and lower the risk of heart problems in people with kidney failure who are on dialysis. It may help if you have diabetes or heart disease and have high inflammation levels.
This trial tests a new study drug called AZD1613 for adults with a certain type of kidney disease (ADPKD). Researchers want to see if it is safe, how the body handles it, and what the right dose might be.
This study tests a new medicine (BI 690517) combined with empagliflozin to see if it can help protect the heart and kidneys in people with chronic kidney disease. It may slow down kidney disease progression and reduce heart risks.
Hear when a new Atherosclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.